



## Media Release

12 December 2010

### Australian clinical trial software to be available in Chinese

Australian clinical trial software company Evado has entered a partnership with Taiwan's leading clinical research organisation, FUGA Biotechnology.

The partnership will give FUGA exclusive distribution rights to represent Evado in Taiwan. FUGA and Evado also agreed to jointly develop a Chinese version of Evado in 2011.

Ms Lily Peng, the President of FUGA, said she is very excited to have this collaboration with Evado.

"It will bring an easy-to-use adaptable clinical trials software application to the Taiwan market place," she said.

Ms Jennie Anderson, CEO of Evado, said that the agreement extends to the localisation of the software for the Taiwanese regulatory environment.

"This is a great opportunity to work with a world class CRO that is extremely well respected in Taiwan," she said.

FUGA will sell and implement the Evado Clinical Trial Software for their clients and for members of the Taiwan Biotechnology Service and Business Trade Association. Evado's award-winning applications will be available in Taiwan as stand-alone versions and as Software-as-a-Service.

This agreement builds on Evado's future potential in Asia. Having established sales channels in Singapore to meet demand for clinical trials software in the ASEAN region, this agreement builds on Evado's future potential in Asia.

### ENDS

For further information or interviews:  
Jennie Anderson, CEO Evado Pty Ltd.  
T: +613 (03) 9329 6626  
E: [jennie@evado.com.au](mailto:jennie@evado.com.au)  
W: [www.evado.com.au](http://www.evado.com.au)

*Evado® Pty Ltd, Level 1, 530 Lonsdale Street, Melbourne VIC, 3000.*

## **About Evado**

With the costs and speed of clinical research increasing, any data collection solution needs to be user-friendly, efficient, economical, and to meet strict requirements around auditing.

The Evado electronic data capture system meets all those criteria and more, in a simple package designed to improve productivity cost effectively, helping get new medical therapies and devices to market faster and economically.

Evado, an intuitive web-based clinical trials application has been built on the foundations of good clinical practice. Evado saves money by providing researchers with a simple user friendly interface that is faster to configure than the more complex systems.

Evado improves the quality of life for patients by providing researchers with a simplified approach for the accurate collection of data designed to bring new medical therapies and devices to market faster.

The software was developed with assistance from universities, CRO's, Microsoft and Intel. Evado maps the workflow of subjects from enrollment through to trial completion with the functionality and reliability of the larger systems at a fraction of their cost.

Evado's customers are research institutes, universities, small and large drug developers and medical device manufacturers all of whom use Evado for pre-clinical through to late stage trials and post market studies.

Evado has been successfully audited against the requirements of the TGA, FDA 21CFR and ICH GCP.

Evado can be internally hosted by a customer, or externally hosted as a Software-As-A-Service (SAAS) application, e.g. a cloud-computing environment.

## **About FUGA Biotechnology Co. Ltd.**

FUGA was founded in 2002 as a CRO company. The company has an experienced team that provides professional and high quality service from concept to market.

The company also supports the biotechnology industry by providing consulting services to solve problems. They are uniquely placed to undertake market, technology and legal assessments.

FUGA services include: preclinical study services; GLP, GTP, GMP consulting; clinical trial design and management; medical regulation consulting; medical product development and commercialization consulting; and quality systems consulting.

FUGA specialises in a number of fields in the biotechnology and pharmaceutical industry. These include medical devices, regenerative medicine (tissue engineering), cell therapy and gene therapy, health food and cosmeceuticals.